South Korea
· Delayed Price · Currency is KRW SyntekaBio Statistics
Total Valuation
SyntekaBio has a market cap or net worth of KRW 91.25 billion. The enterprise value is 78.52 billion.
| Market Cap | 91.25B |
| Enterprise Value | 78.52B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SyntekaBio has 15.26 million shares outstanding. The number of shares has increased by 10.75% in one year.
| Shares Outstanding | 15.26M |
| Shares Change (YoY) | +10.75% |
| Shares Change (QoQ) | +13.79% |
| Owned by Insiders (%) | 17.27% |
| Owned by Institutions (%) | 1.90% |
| Float | 12.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 2.88 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -10.58 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -3.47 |
Financial Position
The company has a current ratio of 1.10, with a Debt / Equity ratio of 0.22.
| Current Ratio | 1.10 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.31 |
| Interest Coverage | -16.98 |
Financial Efficiency
Return on equity (ROE) is -22.07% and return on invested capital (ROIC) is -19.38%.
| Return on Equity (ROE) | -22.07% |
| Return on Assets (ROA) | -14.59% |
| Return on Capital (ROIC) | -19.38% |
| Revenue Per Employee | 1.97M |
| Profits Per Employee | -117.79M |
| Employee Count | 63 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.58% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -52.58% |
| 50-Day Moving Average | 6,320.80 |
| 200-Day Moving Average | 9,494.00 |
| Relative Strength Index (RSI) | 41.06 |
| Average Volume (20 Days) | 45,664 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SyntekaBio had revenue of KRW 124.38 million and -7.42 billion in losses. Loss per share was -899.75.
| Revenue | 124.38M |
| Gross Profit | 121.82M |
| Operating Income | -12.80B |
| Pretax Income | -7.42B |
| Net Income | -7.42B |
| EBITDA | -10.72B |
| EBIT | -12.80B |
| Loss Per Share | -899.75 |
Balance Sheet
The company has 19.75 billion in cash and 7.02 billion in debt, giving a net cash position of 12.72 billion or 833.83 per share.
| Cash & Cash Equivalents | 19.75B |
| Total Debt | 7.02B |
| Net Cash | 12.72B |
| Net Cash Per Share | 833.83 |
| Equity (Book Value) | 31.63B |
| Book Value Per Share | 2,073.02 |
| Working Capital | 1.88B |
Cash Flow
In the last 12 months, operating cash flow was -8.75 billion and capital expenditures -13.88 billion, giving a free cash flow of -22.64 billion.
| Operating Cash Flow | -8.75B |
| Capital Expenditures | -13.88B |
| Free Cash Flow | -22.64B |
| FCF Per Share | -1,483.53 |
Margins
| Gross Margin | 97.94% |
| Operating Margin | -10,288.07% |
| Pretax Margin | -5,966.30% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | -18,198.95% |
Dividends & Yields
SyntekaBio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -10.75% |
| Shareholder Yield | -10.75% |
| Earnings Yield | -15.05% |
| FCF Yield | -24.81% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
SyntekaBio has an Altman Z-Score of 2.41. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.41 |
| Piotroski F-Score | n/a |